All In Biotech

Drug Trial Radar · NCT06226350

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

An Open, Single-arm, Multicenter Phase II Trial of Efficacy and Safety of F520 Monotherapy in the Treatment of Advanced, Persistent, Recurrent, or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Mar 4, 2021

Primary completion

Dec 5, 2023

Study completion Jan 3, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was an open, single-arm, enriched, multicenter Phase II study.

Conditions

  • Cervical Cancer

Interventions

  • Recombinant Humanized Anti-PD-1 Monoclonal Antibody InjectionDrug

    F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective tumor response rate (ORR) assessed by RECIST1.1Time frame: approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shandong New Time Pharmaceutical Co., LTD

    Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.